Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
Kimberley El, Jonathan D. Douros, Francis S. Willard, et al.
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 945-954
Open Access | Times Cited: 66

Showing 26-50 of 66 citing articles:

Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss
Jordan Wean, Allison H. Kowalsky, Rhianna C. Laker, et al.
Molecular Metabolism (2024), pp. 102074-102074
Open Access | Times Cited: 5
Seeking satiety: From signals to solutions
Matthias H. Tschöp, Jeffrey M. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 723
Closed Access | Times Cited: 12
GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease
Stephan Sachs, A. Götz, Brian Finan, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice
Naima S. Dahir, Yijun Gui, Yanan Wu, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 14
Open Access | Times Cited: 4
Exploring neutrophils as therapeutic targets in cardiometabolic diseases
Mattia Albiero, Andrea Baragetti
Trends in Pharmacological Sciences (2025)
Closed Access
Maturity‐Onset Diabetes of the Young (MODY) With HNF1B p.Glu105Lys Mutation Achieving Significant Insulin Reduction on Tirzepatide: A Case Report
Mihiro Sue, Mayu Watanabe, Ayumi Inoue, et al.
Clinical Case Reports (2025) Vol. 13, Iss. 2
Open Access
The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
Jonathan D. Douros, Jonathan N. Flak, Patrick J. Knerr
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Determination of glucose in exhaled breath and saliva by ion chromatography
Jianjun Xu, Chaoyan Lou, Yue Zhuo, et al.
Chinese Journal of Chromatography (2025) Vol. 43, Iss. 3, pp. 245-251
Closed Access
Development of a long-acting unbiased GIP receptor agonist for studies of GIP’s role in bone metabolism
Esther Karen Tordrup, Sarina Gadgaard, Johanne Agerlin Windeløv, et al.
Biochemical Pharmacology (2025), pp. 116893-116893
Closed Access
Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data
Ioanna A. Anastasiou, Georgia Argyrakopoulou, Μaria Dalamaga, et al.
Current Obesity Reports (2025) Vol. 14, Iss. 1
Open Access
ANTI-OBESITY MEDICATIONS IN ADULT AND PEDIATRIC OBESITY AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Natalie Rodríguez, Phillipp Hartmann
Pharmacological Reviews (2025), pp. 100058-100058
Open Access
GLP-1-based therapies for diabetes, obesity and beyond
Daniel J. Drucker
Nature Reviews Drug Discovery (2025)
Closed Access
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, et al.
Medicina (2023) Vol. 59, Iss. 10, pp. 1789-1789
Open Access | Times Cited: 9
The unexpected role of GIP in transforming obesity treatment
Inuk Zandvakili, Diego Pérez–Tilve
Trends in Endocrinology and Metabolism (2024)
Closed Access | Times Cited: 3
Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches
Meghan D. Althoff, K.M. Gaietto, Fernando Holguín, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 210, Iss. 10, pp. 1186-1200
Closed Access | Times Cited: 3
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
Kyle W. Sloop, Amy L. Cox, David B. Wainscott, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 778
Closed Access | Times Cited: 3
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt
Peptides (2024) Vol. 174, pp. 171168-171168
Closed Access | Times Cited: 2
Paracrine signaling by pancreatic islet cilia
Samantha E. Adamson, Jing W. Hughes
Current Opinion in Endocrine and Metabolic Research (2024) Vol. 35, pp. 100505-100505
Open Access | Times Cited: 2
Evaluating GIP and glucagon as key regulators of insulin secretion in the pancreatic islet
Sophie L. Lewandowski, Kimberley El, Jonathan E. Campbell
AJP Endocrinology and Metabolism (2024) Vol. 327, Iss. 1, pp. E103-E110
Closed Access | Times Cited: 2
GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells
Natália da Silva Lima, Alba Cabaleiro, Eva Nóvoa, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 2
Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice
Rola Hammoud, Kiran Deep Kaur, Jacqueline A. Koehler, et al.
JCI Insight (2024)
Open Access | Times Cited: 2
Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases
Sulayman A. Lyons, Jacqueline L. Beaudry
Endocrinology (2023) Vol. 164, Iss. 11
Open Access | Times Cited: 6
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
C. Allard, Daniela Cota, Carmelo Quarta
Drugs (2023) Vol. 84, Iss. 2, pp. 127-148
Closed Access | Times Cited: 6
Lipid regulation of the glucagon receptor family
Affiong I Oqua, Yusman Manchanda, Emma Rose McGlone, et al.
Journal of Endocrinology (2024) Vol. 261, Iss. 3
Open Access | Times Cited: 1
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity
Robert H. Gaffey, Afua K. Takyi, Alpana P. Shukla
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 8, pp. 757-773
Closed Access | Times Cited: 1

Scroll to top